Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Study of Remibrutinib (LOU064) in Healthy Volunteers and Atopic Dermatitis
NCT03918980Phase 1Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of remibrutinib in atopic dermatitis (AD) (10 arms), sponsored by Novartis. Primary endpoint: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 50 days. Started Aug 2016; status: completed.
02
Drugs
remibrutinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03918980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918980.